Collaboration, License, Co-Promotion and Other Commercial Agreements - Summary (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Revenue	$ 79,943	$ 68,730
Collaborative arrangements revenue
Revenues:
Revenue	74,445	66,152
Collaborative arrangement, other agreements
Revenues:
Revenue	354	947
Sale of active pharmaceutical ingredient
Revenues:
Revenue	5,498	2,578
Allergan | North America | Collaborative arrangements revenue
Revenues:
Revenue	71,692	64,785
Allergan | North America | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	71,692	64,785
Allergan | Europe and Other | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	643	420
AstraZeneca | Sale of active pharmaceutical ingredient
Revenues:
Revenue		3
AstraZeneca | China, Hong Kong, and Macau | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	332
AstraZeneca | China, Hong Kong, and Macau | Sale of active pharmaceutical ingredient
Revenues:
Revenue	5,498
Astellas Pharma Inc. | Japan | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	479
Astellas Pharma Inc. | Japan | Sale of active pharmaceutical ingredient
Revenues:
Revenue		$ 2,575
Alnylam | Collaborative arrangement, co-promotion and other agreements
Revenues:
Revenue	$ 945